Introduction: when did the baby formula shortage end
The U.S. baby formula shortage began to ease in mid‑2022, with notable improvements in availability from July through September, but full recovery was uneven across brands and retailers. The most acute supply constraints largely subsided by late 2022, though some disruptions persisted into 2023 and a secondary tightening occurred in early 2023 after Abbott’s voluntary recall. As of mid‑2024, the market is largely stabilized, with better shelf availability and reduced emergency consultations, yet specific products and store formats can still experience intermittent gaps. This evergreen explainer outlines the key phases, drivers, and current status of the shortage.
Timeline of the shortage and recovery
2021: Emergence and escalation
Supply strain became evident in late 2021 and intensified in the first half of 2022. Factors included pandemic‑related logistics disruptions, labor shortages, a major production shutdown at Abbott’s Sturgis, Michigan plant in February 2022, and a product recall that narrowed market options.
2022: Peak stress and initial recovery
The shortage peaked in the spring of 2022, with national sell‑outs and widespread scarcity reported in April and May. Federal intervention, including the Defense Production Act, import expansions, and the FDA’s resolution of the Abbott recall, helped restore output. By July and August, distributions from manufacturers rose, and retailers began to report improved availability.
Late 2022: Continued but moderated gaps
While broad availability improved, parents still faced difficulty finding specific formulas, particularly specialty and extensively hydrolyzed products. Retailers implemented purchase limits, and some hospital and WIC channel allocations remained constrained into October and November.
2023 and early 2024: Stabilization and minor tightening
Supply largely stabilized through 2023, with shelf availability becoming more consistent. In early 2023, another tightening occurred after Abbott’s voluntary recall, prompting a brief increase in scarcity for certain products. By mid‑2024, the market had largely returned to pre‑shortage levels in most channels, though some niche products and smaller retailers can still experience intermittent gaps.
Drivers of the shortage and recovery levers
The shortage was driven by a combination of a major production halt, supply chain bottlenecks, import delays, and shifts in infant feeding behaviors. Recovery relied on multiple levers: restarting domestic production, expanding imports, easing FDA constraints, increased manufacturing capacity, and adjustments to distribution and retail policies. The interplay of these factors explains the uneven timeline across regions and product types.
Current status as of mid‑2024
As of mid‑2024, national availability of standard infant formulas is largely restored, with retailers reporting fewer stockouts. Specialty formulas, particularly those for medical needs, may still face longer lead times and occasional backorders. Parents continue to experience variability depending on retailer, region, and specific formulation. Ongoing monitoring and contingency planning remain important given the consolidated manufacturing base and susceptibility to future disruptions.
Practical guidance for caregivers
- Check multiple retailers, including larger chains and smaller neighborhood stores, as availability varies.
- Confirm that any substitute formula is approved for your infant’s needs and, if relevant, recommended by a pediatrician or dietitian.
- Enroll in retailer waitlists and loyalty programs to receive notifications when products arrive.
- Use telehealth or local WIC clinics for guidance on finding suitable alternatives if needed.
Key metrics at a glance
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Shortpeak start | Mid‑2022 (widespread scarcity by April–May) | Industry reports and FDA updates |
| Notable easing | July–September 2022 | Retailer and government statements |
| Major recall | February 2022 (Abbott Nutricia Sturgis) | FDA and Abbott announcements |
| Import expansion | 2022–2023 (relaxation of certain FDA requirements) | FDA policy updates |
| Market stabilization | Late 2022 onward with intermittent tightening in early 2023 | Retail audits and supply chain analyses |
Permanent changes and ongoing considerations
The shortage accelerated shifts in sourcing, retail practices, and care pathways. Insurers and providers increased use of telehealth and prior‑authorization flexibilities. Parents became more adept at navigating alternatives and substitutions. While the acute crisis has passed, stakeholders emphasize maintaining resilient supply, monitoring concentration risk in manufacturing, and preserving pathways for specialty formulas to reduce the risk of future widespread scarcity.